Thrombo-inflammation in Acute Neurovascular Diseases: Definition of New Therapeutic Targets (TARGETS)

The objective of this observational study is to compare the relative concentrations of various thrombo-inflammatory markers at different follow-up time points in:

* patients with or without delayed cerebral ischemia after subarachnoid hemorrhage, and * patients with or without rapid progression of necrotic volume after an ischemic stroke due to large- or medium-vessel occlusion in the anterior circulation.

The main question this study aims to answer is: How do thrombo-inflammatory marker concentrations evolve over time and differ between patients? Researchers will compare patients with or without delayed cerebral ischemia after subarachnoid hemorrhage, as well as patients with or without rapid progression of necrotic volume following an ischemic stroke due to large- or medium-vessel occlusion in the anterior circulation, to determine whether there are differences in thrombo-inflammatory marker concentrations and in their evolution over time.

Participants will undergo blood sampling at five different time points. In addition, participants will complete a Montreal Cognitive Assessment (MoCA) questionnaire during the 3-month follow-up visit.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Ischemic Stroke Ischemic Stroke of Large or Medium Vessels Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Stroke Subarachnoid Hemorrhage Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 18 years or older
Admitted within 8 hours of an acute ischemic stroke (AIS) due to large-vessel occlusion (LVO) or medium-vessel occlusion (MeVO) of the anterior circulation, with a NIHSS (National Institutes of Health Stroke Scale) score > 5 (M1, M2, M3, A1, A2, A3, P1, P2)
Or admitted within 36 hours of acute symptoms related to aneurysmal subarachnoid hemorrhage (SAH)

Exclusion criteria

Patients with pre-existing functional and/or cognitive disability (modified Rankin Scale, mRS > 1)
Patients under legal protection or guardianship
Patients with secondary hemorrhagic transformation of an acute ischemic stroke

Patients with acute ischemic stroke and NIHSS > 5 without LVO or MeVO of the anterior circulation on imaging will be secondarily excluded. Perfusion imaging will not be performed as part of the research protocol. Excluded patients will be replaced.

Treatment and study plan

Primary outcomes

Investigation of changes in thrombo-inflammatory marker concentrations between patients and over time.

Time frame: From enrollment to Month 3 visit

Investigation of changes in thrombo-inflammatory marker concentrations between patients and over time.

Study contacts

Contact information is provided by the study sponsor or research team.

François Delvoye, MD, PhD

CONTACT

[email protected]

04/3236630

Simon Detriche, PhD

CONTACT

[email protected]

043236684

Sponsors and collaborators

Lead sponsor

François Delvoye

Other

Registry information

Official study title

Thrombo-inflammation Des Maladies Neurovascualires aiguës : définition de Nouvelles Cibles thérapeutiques (TARGETS)

Important dates

Study start: 2026
Primary completion: 2032
Study completion: 2032
First posted: Jan 21, 2026
Registry last updated: Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting